EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

Safety and dose escalation of the targeted oncolytic adenovirus OBP-301 for refractory advanced liver cancer: Phase I clinical trial

Jeong Heo, Ja-Der Liang, Chang Won Kim, Hyun Young Woo, I-Lun Shih, Tung-Hung Su, Zhong-Zhe Lin, So Young Yoo, Stanley Chang, Yasuo Urata, Pei-Jer Chen

Molecular Therapy · 2023

DOI: 10.1016/j.ymthe.2023.04.006 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Molecular Therapy, 2023. Verfasst von Jeong Heo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, College of Medicine, Pusan National University and Biomedical Research Institute, Pusan National University Hospital…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Oncolytic Virotherapy, Oncolytic Viruses. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Research Foundation of Korea, Ministry of Science, ICT and Future Planning.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBP-301 is an oncolytic adenovirus modified to replicate within cancer cells and lyse them. This open-label, non-comparative, phase I dose-escalation trial aimed to assess its safety and optimal dosage in 20 patients with advanced hepatocellular carcinoma. Good tolerance was shown with a maximum tolerated dose of 6 × 1012 viral particles. The most common treatment-emergent adverse events were influenza-like illness, pyrexia, fatigue, decreased platelet count, abdominal distension, and anemia. Cohorts 4 and 5 had approximately 50% higher levels of CD8+ T cells in the peripheral blood after injection. The best target response occurred in 14 patients, 4 of whom had progressive disease. Multiple intratumoral injections of OBP-301 were well tolerated in patients with advanced hepatocellular carcinoma. The stable disease rate for the injected tumors was greater than the overall response rate, even with no obvious tumor response. OBP-301 might have a greater impact on local response as histological examination revealed that the presence of OBP-301 was consistent with the necrotic area at the injection site. Increased infiltration of CD8+ T cells and

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsOncolytic VirotherapyOncolytic VirusesTelomeraseHumansAdenoviridaeCell Line, Tumor

Stichwörter der Autor:innen

OBP-301advanced hepatocellular carcinomaclinical and translationalhTERT promoteroncolytic adenovirussuratodenoturavtelomerase reverse transcriptase genetumor microenvironment

Substanzen

Telomerase

Autor:innen und Institutionen

  • Department of Internal Medicine, College of Medicine, Pusan National University and Biomedical Research Institute, Pusan National University Hospital, Busan, Republic of Korea. Electronic address: jheo@pusan.ac.kr.
  • Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • Department of Radiology, College of Medicine, Pusan National University, Busan, Republic of Korea.
  • Department of Internal Medicine, College of Medicine, Pusan National University and Biomedical Research Institute, Pusan National University Hospital, Busan, Republic of Korea.
  • Department of Medical Imaging, National Taiwan University Hospital, Taipei, Taiwan.
  • Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.

Förderung

  • National Research Foundation of Korea
  • Ministry of Science, ICT and Future Planning

Zitieren

APA

Heo, J., Liang, J. D., Kim, C. W., Woo, H. Y., Shih, I. L., Su, T. H., Lin, Z. Z., Yoo, S. Y., Chang, S., Urata, Y., & Chen, P. J. (2023). Safety and dose escalation of the targeted oncolytic adenovirus OBP-301 for refractory advanced liver cancer: Phase I clinical trial. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2023.04.006

Vancouver

Heo J, Liang JD, Kim CW, Woo HY, Shih IL, Su TH, et al. Safety and dose escalation of the targeted oncolytic adenovirus OBP-301 for refractory advanced liver cancer: Phase I clinical trial. Molecular Therapy. 2023. doi:10.1016/j.ymthe.2023.04.006

BibTeX
@article{Heo2023,
  author = {Heo, Jeong and Liang, Ja-Der and Kim, Chang Won and Woo, Hyun Young and Shih, I-Lun and Su, Tung-Hung and Lin, Zhong-Zhe and Yoo, So Young and Chang, Stanley and Urata, Yasuo and Chen, Pei-Jer},
  title = {Safety and dose escalation of the targeted oncolytic adenovirus OBP-301 for refractory advanced liver cancer: Phase I clinical trial},
  journal = {Molecular Therapy},
  year = {2023},
  doi = {10.1016/j.ymthe.2023.04.006}
}
Kostenlos starten →